ViVerita Therapeutics has announced a new research collaboration with Boehringer Ingelheim.

维维瑞塔治疗公司宣布与勃林格殷格翰达成新的研究合作。

The partnership aims to speed up the discovery and validation of new therapeutic targets in cancer treatment.

该合作旨在加速癌症治疗中新的治疗靶点的发现和验证。

As part of the agreement, ViVerita will use its advanced in vivo CRISPR-based discovery platform to study a selection of potential cancer targets provided by Boehringer Ingelheim. These targets will be tested under conditions that closely mimic the real environment inside the body, offering a more accurate understanding of their potential effectiveness..

根据协议，ViVerita 将使用其先进的基于体内 CRISPR 的发现平台，研究由勃林格殷格翰提供的部分潜在癌症靶点。这些靶点将在高度模拟人体内部真实环境的条件下进行测试，从而更准确地了解它们的潜在有效性。

Cancer remains a leading global health challenge, accounting for one in every six deaths worldwide. Despite ongoing efforts, treatment options for many forms of cancer remain limited. One of the main reasons is that most current drug discovery efforts focus on a narrow group of well-known targets. This collaboration seeks to widen the scope by exploring new, less-understood targets that may lead to more effective treatments..

癌症仍然是全球健康的主要挑战之一，占全球每六例死亡中的一例。尽管不断有新的努力，许多类型的癌症的治疗选择仍然有限。其中一个主要原因是目前大多数药物研发工作都集中在一组狭窄的、已知的靶点上。本次合作旨在通过探索新的、尚未充分理解的靶点来拓宽范围，这可能会带来更有效的治疗方法。

Traditional methods of identifying cancer targets often rely on cell lines grown in lab settings. While useful, these methods do not always reflect the complex conditions found in the body, particularly within the tumour microenvironment. As a result, many promising targets identified in vitro fail to deliver results when tested in vivo..

传统识别癌症靶点的方法通常依赖于在实验室环境中培养的细胞系。尽管这些方法很有用，但它们并不总能反映人体内的复杂条件，尤其是在肿瘤微环境中的情况。因此，许多在体外识别出的有希望的靶点在体内测试时往往无法取得预期效果。

ViVerita’s platform offers a solution by combining large-scale genetic screening with disease models that more closely represent real-life cancer conditions. This approach allows for the discovery and testing of new cancer-driving targets that are difficult to identify using conventional tools.

ViVerita的平台通过将大规模基因筛查与更贴近真实癌症状况的疾病模型相结合，提供了一种解决方案。这种方法能够发现并测试使用传统工具难以识别的新型致癌靶点。

The partnership supports Boehringer Ingelheim’s ongoing strategy to uncover clinically relevant cancer mechanisms and develop innovative treatments for patients with high unmet medical needs. The collaboration is expected to enhance the development of first-in-class therapies by focusing on previously overlooked biological pathways in cancer..

该合作支持了勃林格殷格翰持续的战略，即揭示临床上重要的癌症机制，并为那些医疗需求未得到满足的患者开发创新疗法。通过关注癌症中先前被忽视的生物通路，此次合作有望加速首创疗法的开发。

Through this alliance, both companies aim to make meaningful progress in cancer research and offer new hope to patients around the world.

通过这一联盟，两家公司旨在癌症研究方面取得有意义的进展，并为世界各地的患者提供新的希望。

Source: prnewswire.com

来源：prnewswire.com